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Background
Low molecular weight CCR5 ligands inhibit R5-tropic
HIV-1 entry into cells. They bind to regions of CCR5
separate from the viral envelope gp120 binding site and
would act by an allosteric mechanism, i.e. by inducing
CCR5 conformational changes, which in turn might
reduce CCR5 affinity for gp120. Indeed, these com-
pounds block allosterically chemokine (CHK) binding to
CCR5. Some of them are inverse agonists for CCR5, and
stabilize G-protein uncoupled, inactive CCR5. But,
whether all of them are inverse agonists and to what
extent inverse agonism (i.e. G protein uncoupling) con-
tributes to antiviral activity is unclear.
Methods
Standard protocols reported elsewhere were used.
35S-
gp120 from the Bx08 strain was produced using a SFV
type vector in BHK cells. Viral progeny with the renilla-
luciferase gene was used to infect U87 cells or PBMCs.
Results
The inhibitors Maraviroc (MVC) and TAK779 are weak
and full inverse agonists for CCR5, respectively, and sta-
bilize distinct receptor conformations. TAK and MVC
promote CHK dissociation from the receptor with an
efficiency correlating with their inverse agonist efficacy.
However, we found that gp120 is a CCR5 antagonist, so
that its dissociation does not depend on CCR5 uncou-
pling from G-proteins. Kinetic studies showed that
gp120 dissociation from CCR5 (koff =0 . 5 9h
-1)i s
enhanced in the presence of TAK (5.4 h
-1), and to a les-
ser extent by MVC (1.6 h
-1). However, in displacement
experiments of
35S-gp120 binding, affinities of MVC and
T A Kf o rC C R 5a r ei nt h es a m er a n g e( I C 50~7 vs 21
nM), although MVC is 100-fold more potent than TAK
for inhibiting HIV infection.
Discussion
Our results imply that gp120 has a lower affinity for
TAK- than for MVC-bound CCR5, although TAK has a
weaker antiviral activity. Thus, blocking of infection by
these compounds does not solely rely on their ability to
reduce affinity of CCR5 for gp120.
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